Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

por Pellegrino, Benedetta, Mateo, Joaquin, Serra, Violeta, Balmaña, Judith
Publicado 2019

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity

por Wright, Sarah Christine Elisabeth, Vasilevski, Natali, Serra, Violeta, Rodon, Jordi, Eichhorn, Pieter Johan Adam
Publicado 2021

Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity

por Mair, Barbara, Konopka, Tomasz, Kerzendorfer, Claudia, Sleiman, Katia, Salic, Sejla, Serra, Violeta, Muellner, Markus K., Theodorou, Vasiliki, Nijman, Sebastian M. B.
Publicado 2016

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

por Mateo, Lidia, Duran-Frigola, Miquel, Gris-Oliver, Albert, Palafox, Marta, Scaltriti, Maurizio, Razavi, Pedram, Chandarlapaty, Sarat, Arribas, Joaquin, Bellet, Meritxell, Serra, Violeta, Aloy, Patrick
Publicado 2020

Modulation of telomere protection by the PI3K/AKT pathway

por Méndez-Pertuz, Marinela, Martínez, Paula, Blanco-Aparicio, Carmen, Gómez-Casero, Elena, Belen García, Ana, Martínez-Torrecuadrada, Jorge, Palafox, Marta, Cortés, Javier, Serra, Violeta, Pastor, Joaquin, Blasco, Maria A.
Publicado 2017

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

por Bellio, Chiara, Emperador, Marta, Castellano, Pol, Gris-Oliver, Albert, Canals, Francesc, Sánchez-Pla, Alex, Zamora, Esther, Arribas, Joaquín, Saura, Cristina, Serra, Violeta, Tabernero, Josep, Littlefield, Bruce A., Villanueva, Josep
Publicado 2022

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

por Kramer, Claire JH, Llop‐Guevara, Alba, Yaniz‐Galende, Elisa, Pellegrino, Benedetta, ter Haar, Natalja T, Herencia‐Ropero, Andrea, Campanini, Nicoletta, Musolino, Antonino, Bosse, Tjalling, Leary, Alexandra, Serra, Violeta, Vreeswijk, Maaike PG
Publicado 2023

Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours

por Groelly, Florian J, Porru, Manuela, Zimmer, Jutta, Benainous, Hugo, De Visser, Yanti, Kosova, Anastasiya A, Di Vito, Serena, Serra, Violeta, Ryan, Anderson, Leonetti, Carlo, Bruna, Alejandra, Biroccio, Annamaria, Tarsounas, Madalena
Publicado 2022

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

por Rodriguez, María Jimena, Perrone, María Cecilia, Riggio, Marina, Palafox, Marta, Salinas, Valeria, Elia, Andrés, Salgueiro, Natali Daiana, Werbach, Andrea Eugenia, Marks, María Paula, Kauffman, Marcelo A., Vellón, Luciano, Serra, Violeta, Novaro, Virginia
Publicado 2023

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

por Wang, Yifan, Bernhardy, Andrea J., Nacson, Joseph, Krais, John J., Tan, Yin-Fei, Nicolas, Emmanuelle, Radke, Marc R., Handorf, Elizabeth, Llop-Guevara, Alba, Balmaña, Judith, Swisher, Elizabeth M., Serra, Violeta, Peri, Suraj, Johnson, Neil
Publicado 2019

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

por Winkler, Claudia, Armenia, Joshua, Jones, Gemma N., Tobalina, Luis, Sale, Matthew J., Petreus, Tudor, Baird, Tarrion, Serra, Violeta, Wang, Anderson T., Lau, Alan, Garnett, Mathew J., Jaaks, Patricia, Coker, Elizabeth A., Pierce, Andrew J., O’Connor, Mark J., Leo, Elisabetta
Publicado 2020

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

por Aziz, Diar, Portman, Neil, Fernandez, Kristine J., Lee, Christine, Alexandrou, Sarah, Llop-Guevara, Alba, Phan, Zoe, Yong, Aliza, Wilkinson, Ashleigh, Sergio, C. Marcelo, Ferraro, Danielle, Etemadmoghadam, Dariush, Bowtell, David D., Serra, Violeta, Waring, Paul, Lim, Elgene, Caldon, C. Elizabeth
Publicado 2021

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

por Cedrés, Susana, Felip, Enriqueta, Cruz, Cristina, Martinez de Castro, Ana, Pardo, Nuria, Navarro, Alejandro, Martinez-Marti, Alex, Remon, Jordin, Zeron-Medina, Jorge, Balmaña, Judith, Llop-Guevara, Alba, Miquel, Josep M, Sansano, Irene, Nuciforo, Paolo, Mancuso, Francesco, Serra, Violeta, Vivancos, Ana
Publicado 2018

MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer

por Dinami, Roberto, Pompili, Luca, Petti, Eleonora, Porru, Manuela, D'Angelo, Carmen, Di Vito, Serena, Rizzo, Angela, Campani, Virginia, De Rosa, Giuseppe, Bruna, Alejandra, Serra, Violeta, Mano, Miguel, Giacca, Mauro, Leonetti, Carlo, Ciliberto, Gennaro, Tarsounas, Madalena, Stoppacciaro, Antonella, Schoeftner, Stefan, Biroccio, Annamaria
Publicado 2022

Targeting a cell state common to triple-negative breast cancers

por Muellner, Markus K, Mair, Barbara, Ibrahim, Yasir, Kerzendorfer, Claudia, Lechtermann, Hannelore, Trefzer, Claudia, Klepsch, Freya, Müller, André C, Leitner, Ernestine, Macho-Maschler, Sabine, Superti-Furga, Giulio, Bennett, Keiryn L, Baselga, José, Rix, Uwe, Kubicek, Stefan, Colinge, Jacques, Serra, Violeta, Nijman, Sebastian MB
Publicado 2015

Clinical consequences of BRCA2 hypomorphism

por Castells-Roca, Laia, Gutiérrez-Enríquez, Sara, Bonache, Sandra, Bogliolo, Massimo, Carrasco, Estela, Aza-Carmona, Miriam, Montalban, Gemma, Muñoz-Subirana, Núria, Pujol, Roser, Cruz, Cristina, Llop-Guevara, Alba, Ramírez, María J., Saura, Cristina, Lasa, Adriana, Serra, Violeta, Diez, Orland, Balmaña, Judith, Surrallés, Jordi
Publicado 2021

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

por Shah, Jennifer B., Pueschl, Dana, Wubbenhorst, Bradley, Fan, Mengyao, Pluta, John, D’Andrea, Kurt, Hubert, Anna P., Shilan, Jake S., Zhou, Wenting, Kraya, Adam A., Llop Guevara, Alba, Ruan, Catherine, Serra, Violeta, Balmaña, Judith, Feldman, Michael, Morin, Pat J., Nayak, Anupma, Maxwell, Kara N., Domchek, Susan M., Nathanson, Katherine L.
Publicado 2022

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

por Dunn, Shanade, Eberlein, Cath, Yu, Jason, Gris-Oliver, Albert, Ong, Swee Hoe, Yelland, Urs, Cureton, Natalie, Staniszewska, Anna, McEwen, Robert, Fox, Millie, Pilling, James, Hopcroft, Philip, Coker, Elizabeth A., Jaaks, Patricia, Garnett, Mathew J., Isherwood, Beverley, Serra, Violeta, Davies, Barry R., Barry, Simon T., Lynch, James T., Yusa, Kosuke
Publicado 2022

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

por Gómez-Miragaya, Jorge, Palafox, Marta, Paré, Laia, Yoldi, Guillermo, Ferrer, Irene, Vila, Sergi, Galván, Patricia, Pellegrini, Pasquale, Pérez-Montoyo, Hector, Igea, Ana, Muñoz, Purificación, Esteller, Manel, Nebreda, Angel R., Urruticoechea, Ander, Morilla, Idoia, Pernas, Sonia, Climent, Fina, Soler-Monso, María Teresa, Petit, Ana, Serra, Violeta, Prat, Aleix, González-Suárez, Eva
Publicado 2017

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

por Saei, Azad, Palafox, Marta, Benoukraf, Touati, Kumari, Nishi, Jaynes, Patrick William, Iyengar, Prasanna Vasudevan, Muñoz-Couselo, Eva, Nuciforo, Paolo, Cortés, Javier, Nötzel, Christopher, Kumarakulasinghe, Nesaretnam Barr, Richard, John Lalith Charles, Bin Adam Isa, Zul Fazreen, Pang, Brendan, Guzman, Marta, Siqin, Zhou, Yang, Henry, Tam, Wai Leong, Serra, Violeta, Eichhorn, Pieter Johan Adam
Publicado 2018